Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page * g0 P: D) G) a E* K
: ?4 A4 D8 q8 i2 N' i8 d
, f/ d8 W( b5 P0 G; [Sub-category:" H6 a% C. A4 e
Molecular Targets ' e' _! S+ J' p& f; H+ X
. `% Q& p8 p! l- ^) o
1 ^, n8 l5 R& m- f1 YCategory:
4 E7 p+ k2 `, N' q2 fTumor Biology
) R7 H9 W0 ]$ ? u8 N. j/ _* r$ C# V4 }0 i
0 J: B5 s2 t, Z- E7 ~Meeting:
s7 z3 {* C0 h: p2011 ASCO Annual Meeting X& X" ]! f" @( i7 q) r
$ z: {% d) p) b9 P, w& X" Q9 r% r- G) \% I8 V0 V
Session Type and Session Title:1 b1 L* @7 W# M: L2 y9 l# Q3 A& V
Poster Discussion Session, Tumor Biology
% t4 m% M$ a, L; [; e% @2 t; e- r' Z0 Q4 _ N; i
0 r" O) w" f+ x5 Z+ ?
Abstract No:7 w. g' D) w$ a d
10517 $ |' `$ b! L6 T
. M( b& Y. F0 C* I0 j
7 H% m& Q- O$ CCitation:% i/ `" y& `# {' i* {& x
J Clin Oncol 29: 2011 (suppl; abstr 10517)
- Z! c: {+ D$ Q9 `; W
. j6 d7 R/ @* F$ g3 c' _
9 N+ {! Z- w& M3 a, I8 k+ wAuthor(s):
* N" a1 X" ~. ZJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 7 d- U# ]( J( [7 J0 u0 E7 H
/ B( j( T( r9 K1 x' f: \- ]
. U# d. m3 i( w1 J1 Q
* X- x; f' E+ b. K8 \
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
) r" H0 p& |$ J( a% ^- ~
; P$ `/ Y2 e/ F$ @9 UAbstract Disclosures
2 L! h& [2 I( Z+ i
4 Q6 O5 r7 p% r3 p$ n' K \7 eAbstract:
. }+ ]+ g& S& \+ s/ }* e0 H$ |6 `$ B( W2 E
' ]6 I$ c" L' R. L4 P3 M
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ K8 `8 B/ X" p. h7 {3 j) g/ k9 `4 \0 [
# `3 Q6 v/ i7 E3 D7 ~ 7 d# V3 L0 E: S; z6 ^: X% {9 L- N
|